A study for people looking to transition from Buprenorphine maintenance to VIVITROL

A study for people looking to transition from Buprenorphine maintenance to VIVITROL
Recruiting
18 years - 60 years
All
Phase 3
1 Location

Brief description of study

Up to 9 weeks, including Screening (up to 3 weeks), up to 2 weeks for Lead-in Period and residential Treatment Period receiving decreasing doses of Buprenorphine and increasing doses of either active or placebo Naltrexone, 4-5 days for VIVITROL induction and post-VIVITROL monitoring, and a 4-week outpatient follow-up period.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Opioid Addiction, Opioid-Related Disorders
  • Age: 18 years - 60 years
  • Gender: All
Updated on 19 Feb 2024. Study ID: 825716

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.